In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Vaccitech plc

Finance Watch: VC Fundraising Dips In Q2, But Mega-Deal Pace Is Strong

Private Company Edition: The amount of venture capital raised by biopharma firms fell but individual companies grabbed a lot of cash, making for a remarkable Q2 relative to pre-pandemic times. Recent Q3 rounds includes Frontera’s $160m series B. Also, Oxford Science Enterprises added €250m to its fund.

Financing Innovation

Stock Watch: The Stubborn Hurdle Of Chronic Hepatitis B

Most of the money raised by biotech companies to address chronic hepatitis B has resulted in failed programs. But wait, a glimmer of light from yonder pharma breaks.

Stock Watch Vaccines

Funding The Future: Accelerating The Long Walk To Innovation

In Vivo spoke with two company creators working in the biotech industry about their strategies for seeking new science and their funding philosophy when building the biotechs of tomorrow.

New Science StartUps and SMEs

Vaccitech’s Immunotherapy Combo With Opdivo Shows Hepatitis B Promise

The UK company did not profit greatly from its role in COVID-19 vaccine, Vaxzevria, but hopes the same technology can form part of a breakthrough in hepatitis B.

Commercial Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
UsernamePublicRestriction

Register